Renovaro Biosciences Denmark ApS: Financial statements 2014
CVR: 26027322
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
Renovaro Biosciences Denmark ApS (CVR 26027322) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK -8,457,022 and a net result of DKK -11,472,661 compared with DKK -10,561,248 the year before. Equity in the 2014 report amounted to DKK -20,951,214.
- Gross Profit
- DKK -8,457,022
- Profit/Loss
- DKK -11,472,661
- Equity
- DKK -20,951,214
- Total Assets
- DKK 2,898,015
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | -8.5M | -11.5M | -21M | - |
| 2013 | - | -5.6M | -10.6M | -9.5M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
Renovaro Biosciences Denmark ApS has published its annual report for 2013. Gross profit came to DKK -5,558,844, and the net result was DKK -10,561,248.
As of February 12, 2014, is registered as an owner of Renovaro Biosciences Denmark ApS with an ownership share of 100%.
About Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Enochian BioSciences Denmark ApS and DanDrit Biotech ApS. The management consists of David Hershel Weinstein. The company is owned by Lunai Bioworks Inc.. The company has 1 employee (2017). In 2026, the company reported a gross profit of DKK -4,478 and a net result of DKK -1,178,038 compared with DKK -4,629,959 the year before. Equity in the 2026 report amounted to DKK -91,933,986.
